Treatment with Kampo medicine (Keigai-rengyo-to or Seijo-bofu-to) and Azithromycin for Zika virus infection   Short title: Treatment with Kampo medicine and azithromycin for Zika virus infection: Treatment with Kampo medicine and Azithromycin for Zika virus infection

Ohe, Masashi

doi:10.51094/jxiv.4321

##article.authors##

Ohe, Masashi Department of Internal Medicine, JCHO Hokkaido Hospital

DOI:

https://doi.org/10.51094/jxiv.4321

キーワード:

Zika virus、 Kampo medicine、 azithromycin

抄録

Zika virus (ZIKV) is a mosquito‑borne flavivirus with structural proteins (C, prM/M, E) and nonstructural proteins (NS1–NS5) essential for host entry, immune evasion, and RNA replication. NS1 multimers and the NS2B‑NS3 and NS5 enzymes are major determinants of pathogenicity and antiviral targets. After decades of low circulation, ZIKV caused major outbreaks from 2007 to 2016, including the Brazil epidemic that revealed strong associations with Guillain–Barré syndrome and congenital Zika syndrome, such as microcephaly. Most infections are mild, but diagnosis is complicated by dengue cross‑reactivity, and no approved antiviral or vaccine exists. Research continues into therapies targeting viral enzymes and host pathways. Several phytochemicals in Japanese Kampo medicines show in vitro or in silico anti‑ZIKV activity, including baicalin, apigenin, luteolin, naringenin, berberine, and quercetin. Azithromycin also suppresses ZIKV through interferon induction and anti‑inflammatory effects. These findings suggest potential combination therapies, though clinical trials are needed.

利益相反に関する開示

The authors have no conflicts of interest associated with this article.

ダウンロード *前日までの集計結果を表示します

ダウンロード実績データは、公開の翌日以降に作成されます。

引用文献

de Araujo Dorneles ML, Cardoso-Lima R, Souza PFN, et al. Zika Virus (ZIKV): A New Perspective on the Nanomechanical and Structural Properties. Viruses. 2022 Aug 5;14(8):1727. doi: 10.3390/v14081727. PMID: 36016349; PMCID: PMC9414353.

Chew BLA, Ngoh AQ, Phoo WW, et al. Structural basis of Zika virus NS1 multimerization and human antibody recognition. npj Viruses 2, 14 (2024). https://doi.org/10.1038/s44298-024-00024-6

Bhat EA, Ali T, Sajjad N, Bron P. Insights into the structure, functional perspective, and pathogenesis of ZIKV: an updated review. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:115175.

Masmejan S, Musso D, Vouga M, et al. Zika Virus. Pathogens. 2020 Oct 28;9(11):898. doi: 10.3390/pathogens9110898. PMID: 33126413; PMCID: PMC7692141.

Camacho-Concha N, Santana-Román ME, Sánchez NC, et al. Insights into Zika Virus Pathogenesis and Potential Therapeutic Strategies. Biomedicines. 2023 Dec 15;11(12):3316. doi: 10.3390/biomedicines11123316. PMID: 38137537; PMCID: PMC10741857.

Takayama S, Namiki T, Arita R, et al. Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients. Front Pharmacol. 2022 Nov 9;13:1008946.

Ohe M, Shida H, Yamamoto J, et al. COVID-19 Treated with Minocycline and Saiko-keishi-to: A Case Report. Intern Med J. 2024;31:27-8.

Ohe M, Shida H, Yamamoto J, Seki M, Furuya K. Successful treatment with minocycline and Saiko-keishi-to for COVID-19. J CLIN EXP INVEST. 2023;14(2): em00815. https://doi.org/10.29333/jcei/12999

Yanagi K, Suzuki M, Hasegawa S. (2020). Shingata koronauirusu kansen-shō (COVID 19) no innaikansen ni taisuru keigairengyoto no hassho yobo koka [Preventive effect of Keigairengyoto on nosocomial infection of COVID 19]. Kampo to Saishin Chiryo, 29(2), 131–6.

Tsuchida N, Ohe M. Treatment with Kampo Medicine and Minocycline for Influenza. Intern Med J. 2025;32:162-3.

Ohe M. Drug Repurposing with Minocycline and Japanese Kampo Medicine for Mpox: Predicting Efficacy through In Silico Studies. Intern Med J. 2025;32:2-3.

Ohe M. Multidrug Treatment Using Kampo Medicine for Severe Fever with Thrombocytopenia Syndrome. Preprints 2025, 2025090637. https://doi.org/10.20944/preprints202509.0637.v1

Ohe M. Commentary: Combination Treatment Using Favipiravir for Crimean-Congo Hemorrhagic Fever. https://doi.org/10.51094/jxiv.1594

Ohe M. treatment with Kampo medicine (Keigai-rengyo-to and sho-saiko-to) for Dengue fever. https://doi.org/10.51094/jxiv.3527

Oo A, Teoh BT, Sam SS, Bakar SA, Zandi K. Baicalein and baicalin as Zika virus inhibitors. Arch. Virol. 2019, 164, 585-93.

Kim M, Choi H, Kim YB. Therapeutic targets and biological mechanisms of action of curcumin against Zika virus: in silico and in vitro analyses. Eur. J. Pharmacol. 2021, 904, 174144.

Ahmed SR, Banik A, Anni SM, Chowdhury MMH. Inhibitory potential of plant-derived metabolites against Zika virus: A computational-aided approach. Phytomedicine Plus 2021, 1, 100129.

Cataneo AHD, Kuczera D, Koishi AC, et al. The citrus flavonoid naringenin impairs the in vitro infection of human cells by Zika virus. Sci. Rep. 2019, 9, 16348.

Eberle RJ, Olivier DS, Pacca CC, et al. In vitro study of hesperetin and hesperidin as inhibitors of Zika and Chikungunya virus proteases. PLoS ONE 2021, 16, e0246319.

Batista MN, Braga ACS, Campos GRF, et al. Natural products isolated from oriental medicinal herbs inactivate Zika virus. Viruses 2019, 11, 49.

Zou M, Liu H, Li J, et al. Structure-activity relationship of flavonoid bifunctional inhibitors against Zika virus infection. Biochem. Pharmacol. 2020, 177, 113962.

Khoshnood S, Shirani M, Dalir A, et al. Antiviral effects of azithromycin: A narrative review. Biomedicine & Pharmacotherapy. 2022 Mar 1;147:112682.

Wu YH, Tseng CK, Lin CK, Wei CK, Lee JC, Young KC. ICR suckling mouse model of Zika virus infection for disease modeling and drug validation. PLoS neglected tropical diseases. 2018 Oct 24;12(10):e0006848.

Wang X, Xia S, Zou P, Lu L. Erythromycin estolate inhibits zika virus infection by blocking viral entry as a viral inactivator. Viruses. 2019 Nov 15;11(11):1064.

Treatment with Kampo medicine (Keigai-rengyo-to or Seijo-bofu-to) and Azithromycin for Zika virus infection Short title: Treatment with Kampo medicine and azithromycin for Zika virus infection

Treatment with Kampo medicine and Azithromycin for Zika virus infection